Telix Pharmaceuticals (NASDAQ:TLX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Telix Pharmaceuticals (NASDAQ:TLX) from a hold rating to a sell rating in a research note published on Sunday.

Other equities analysts have also recently issued reports about the company. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Citigroup increased their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Stock Down 0.5%

Shares of TLX opened at $7.85 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The business’s 50 day moving average price is $7.32 and its 200-day moving average price is $8.77. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $20.00.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). On average, equities analysts predict that Telix Pharmaceuticals will post 0.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers raised its position in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd purchased a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth about $89,000. IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $213,000. OLD Mission Capital LLC bought a new stake in Telix Pharmaceuticals during the 4th quarter valued at approximately $111,000. Finally, Private Advisor Group LLC lifted its holdings in Telix Pharmaceuticals by 67.3% in the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after purchasing an additional 16,945 shares in the last quarter.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.